US Patent

US11471471 — Aqueous oral pharmaceutical suspension compositions

Method of Use · Assigned to Reveragen Biopharma Inc · Expires 2040-03-17 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an aqueous oral pharmaceutical suspension composition containing vamorolone Form I and methods for its preparation and use.

USPTO Abstract

Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Drugs covered by this patent

Agamree (VAMOROLONE) · Catalyst Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3747`	—	Agamree

Patent Metadata

Patent number: US11471471
Jurisdiction: US
Classification: Method of Use
Expires: 2040-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Reveragen Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.